Puretech Health Plc  (PRTC)
Other Ticker:  
Price: $26.7300 $1.53 6.071%
Day's High: $26.73 Week Perf: 1.63 %
Day's Low: $ 25.92 30 Day Perf: 5.86 %
Volume (M): 1 52 Wk High: $ 33.07
Volume (M$): $ 21 52 Wk Avg: $24.41
Open: $25.92 52 Wk Low: $17.08

 Market Capitalization (Millions $) 7,478
 Shares Outstanding (Millions) 280
 Employees -
 Revenues (TTM) (Millions $) 16
 Net Income (TTM) (Millions $) -37
 Cash Flow (TTM) (Millions $) 466
 Capital Exp. (TTM) (Millions $) 2

Puretech Health Plc
PureTech Health Plc, founded in 2002, is a biotechnology company that focuses on developing and commercializing innovative treatments for various healthcare challenges. The company aims to address significant medical needs by utilizing strategic partnerships and collaborations with leading academic institutions, scientific entrepreneurs, and industry experts.

PureTech Health has a unique approach to healthcare innovation, employing a cross-disciplinary team of experts in various fields, including biology, medicine, engineering, and data science. This interdisciplinary approach allows the company to explore diverse technologies and treatment modalities, including microbiome-based therapies, targeted drug delivery systems, and digital health solutions.

The company operates through an internal pipeline of wholly-owned subsidiaries, such as Karuna Therapeutics, Gelesis, Vedanta Biosciences, and Akili Interactive, among others. Each subsidiary focuses on a specific therapeutic area or technological platform, allowing for efficient development and commercialization of their respective products.

PureTech Health Plc's innovation-driven business model aims to identify and validate emerging science and technology, shepherd them through clinical development, and ultimately launch them as successful, commercially viable products. With a strong emphasis on collaboration and intellectual property, the company strives to position itself at the forefront of healthcare innovation.

   Company Address: 6 Tide Street Boston 2210 MA
   Company Phone Number: 482-2333   Stock Exchange / Ticker: NASDAQ PRTC
   PRTC is expected to report next financial results on April 27, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Ani Pharmaceuticals Inc

2. Embracing Success: ANI Pharmaceuticals Inc's Remarkable Turnaround in Q4 2023

As a pharmaceutical industry enthusiast and an avid follower of ANI Pharmaceuticals Inc, I am thrilled to report on the recent financial results and business highlights of this major pharmaceutical preparations company. The October to December 31, 2023 fiscal time-frame has proven to be a turning point for ANI Pharmaceuticals Inc, as they have witnessed significant improvements in their earnings and revenue.
Starting with earnings per share, ANI Pharmaceuticals Inc saw a substantial positive shift from $-0.23 a year prior to $0.03 per share in the recent fiscal time-frame. This impressive improvement showcases the company's ability to effectively manage their financial performance and generate profits. Additionally, ANI Pharmaceuticals Inc reported earnings per share of $0.85 compared to $-3.05 in the previous fiscal year, indicating remarkable growth.

Chimerix Inc

Serious headline: Chimerix Inc Sees Decrease in Losses During Fourth Quarter of 2023

Chimerix Inc, a major pharmaceutical preparations company, experienced a decrease in their loss per share for the October to December 31, 2023 interval. The loss per share decreased from $-0.22 to $-0.20 compared to the same period the previous year. Additionally, their income per share improved from $-0.27 to -$0.20 from the prior quarter.
However, the company witnessed a sharp decline in revenue during this interval. The revenue dropped from $0.81 million in the same quarter the previous year to $0.00 million, and sequentially from $0.01 million.

Compass Pathways Plc

Compass Pathways Plc Reports Impressive Fourth Quarter Efforts Amidst Industry Growth

Compass Pathways Plc, a biotechnology company focused on mental health innovation, has experienced significant growth in its share price over the past year. According to recent financial results, the company's shares have risen by 24.72% compared to a year ago, reaching an impressive 69.55% increase in the past 90 days alone. This positive trend is further supported by the fact that Compass Pathways Plc shares are currently trading on the NASDAQ at a significant 22.4% above its 52-week average.
One factor that could potentially contribute to this growth is the company's collaboration with Hackensack Meridian Health (HMH) to optimize the clinical model for COMP360 psilocybin treatment, a psychedelic substance found in magic mushrooms. This collaboration aims to develop an effective treatment model if approved by the FDA, highlighting Compass Pathways' commitment to innovative mental health solutions.

Verona Pharma Plc

Verona Pharma Plc's Financial Successes Propel Growth Amid Lackluster Revenue in Q4 2023

Verona Pharma Plc, a prominent player in the pharmaceutical industry, has recently made strategic moves to strengthen its financial position, enabling continued growth. Despite a minor increase in borrowings, the company has successfully enhanced its Leverage Ratio, surpassing its own average and outperforming 16 competitors within the industry. These developments have significant implications for the company's overall trajectory.
Verona Pharma Plc has managed to boost its Leverage Ratio to 0.11 in the third quarter of 2023. This ratio exceeds the company's typical average and ranks higher than its Leverage Ratio in the previous quarter. What makes this achievement even more noteworthy is that 16 other companies in the industry reported lower Leverage Ratios during the same period, highlighting Verona Pharma's superior financial standing.

Moonlake Immunotherapeutics

Financial Turnaround: Moonlake Immunotherapeutics Reports Significant Decrease in Operating Loss and Diminishing Returns

Moonlake Immunotherapeutics is a small pharmaceutical company that has been making headlines in the Major Pharmaceutical Preparations sector with its latest financial performance. The company has shown significant improvement in its operating loss, decreasing from $-29.927 million in the fourth quarter of 2022 to $-15.028897 million in the same period of 2023. This is a positive sign for Moonlake Immunotherapeutics as it demonstrates a strong commitment to cost-effectiveness and financial stability.
One of the key indicators of Moonlake Immunotherapeutics' potential for growth is the decrease in diminishing returns, which have declined to $-7.887 million in the fourth quarter of 2023 from $-29.644 million in the previous year. This trend suggests that the company is on the right path to becoming a major player in the Healthcare sector. Additionally, the increase in accounts receivable is a promising sign of rising demand for Moonlake Immunotherapeutics' products and services.


Puretech Health Plc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com